RTTNews | Jan 6, 2022 08:45AM EST

08:43 Thursday, January 6, 2022 (RTTNews.com) - Alnylam Pharmaceuticals, Inc. (ALNY) announced a collaboration with Novartis to leverage Alnylam's siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

During the three-year research collaboration, Alnylam will develop and test potential siRNAs using target-specific assays developed by Novartis. Once a lead candidate is identified, further development and clinical research will be conducted by Novartis.

Read the original article on RTTNews ( https://www.rttnews.com/3253252/alnylam-novartis-enter-research-collaboration-to-provide-alternative-to-liver-transplantation.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved